Literature DB >> 15814185

French hormones: progestins and therapeutic variation in France.

Ilana Löwy1, George Weisz.   

Abstract

Western medicine is seen as universally valid, but in reality it displays a wide range of national and local variability. Our paper focuses on one such case of local variation: the widespread use of progestins in France to treat various pre-menopausal conditions as well as for contraception. The case of progestins allows us to explore how specific styles of research may come to dominate a particular local medical culture, and how they are influenced by changing criteria of scientific validity and wider social relations. We argue that in the 1980s and 1990s a single prestigious research-oriented Parisian hospital service played a dominant role in the transformation of progestins into scientifically validated medical practice. This status was not called seriously into question until recently when foreign research on a different form of hormone therapy suggested that risk was associated with their use. We also propose that both the research around and medical use of progestins in France was shaped by the positive attitude of many French women, including feminists, to hormonal therapies and to the non-surgical specialty most closely associated with hormones, medical gynaecology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15814185     DOI: 10.1016/j.socscimed.2004.10.021

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  8 in total

1.  [From a method for family planning to a differentiating lifestyle drug: images of the pill and its consumer in gynaecological advertising since the 1960s in West Germany and France].

Authors:  Lisa Malich
Journal:  NTM       Date:  2012

Review 2.  Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives.

Authors:  Nancy Krieger; Ilana Löwy; Robert Aronowitz; Judyann Bigby; Kay Dickersin; Elizabeth Garner; Jean-Paul Gaudillière; Carolina Hinestrosa; Ruth Hubbard; Paula A Johnson; Stacey A Missmer; Judy Norsigian; Cynthia Pearson; Charles E Rosenberg; Lynn Rosenberg; Barbara G Rosenkrantz; Barbara Seaman; Carlos Sonnenschein; Ana M Soto; Joe Thornton; George Weisz
Journal:  J Epidemiol Community Health       Date:  2005-09       Impact factor: 3.710

3.  Endometriosis and the risk of skin cancer: a prospective cohort study.

Authors:  Leslie V Farland; Simon Lorrain; Stacey A Missmer; Laureen Dartois; Iris Cervenka; Isabelle Savoye; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Marina Kvaskoff
Journal:  Cancer Causes Control       Date:  2017-08-10       Impact factor: 2.506

Review 4.  Progestin and breast cancer risk: a systematic review.

Authors:  Marsha Samson; Nancy Porter; Olubunmi Orekoya; James R Hebert; Swann Arp Adams; Charles L Bennett; Susan E Steck
Journal:  Breast Cancer Res Treat       Date:  2015-12-23       Impact factor: 4.872

5.  Oral progestagens before menopause and breast cancer risk.

Authors:  A Fabre; A Fournier; S Mesrine; J Desreux; A Gompel; M-C Boutron-Ruault; F Clavel-Chapelon
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

Review 6.  Hormone therapy and melanoma in women.

Authors:  Madison S Hill; Alexander M Cartron; Mary Burgoyne; Marcia S Driscoll
Journal:  Int J Womens Dermatol       Date:  2021-06-25

7.  Like mother, like daughter, like granddaughter… Transgenerational ignorance engendered by a defective reproductive health technology.

Authors:  Emmanuelle Fillion; Didier Torny
Journal:  Reprod Biomed Soc Online       Date:  2021-10-30

8.  Adopting an 'unlearner' technology? Knowledge battles over pharmaceutical pain relief in childbirth in post-1968 France.

Authors:  Sezin Topçu
Journal:  Reprod Biomed Soc Online       Date:  2021-04-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.